HLAG anticorps (C-Term) (Biotin)

N° du produit ABIN94381

Détail du produit anti-HLAG anticorps (Biotin)

Antigène: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Épitope: C-Term

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp HLAG est conjugé à/à la Biotin

Application: Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunocytochemistry (ICC)

Specificité: The mouse monoclonal antibody 5A6G7 was generated to a peptide corresponding to C-intron 4-encoded sequence. This antibody does not crossreact with the full-length HLA-G1 isoform and thus allows to distinguish between secreted HLA-G5 and HLA-G6 isoforms from shedded HLA-G1.

Réactivité croisée (Details): Human

Purification: Purified antibody is conjugated with biotin LC-NHS ester under optimum conditions and unconjugated antibody and free biotin are removed by size-exclusion chromatography.

Immunogène: C-terminal amino acid sequence (22-mer) of soluble HLA-G5 and HLA-G6 proteins coupled to ovalbumin.

Clone: 5A6G7

Isotype: IgG1

Information d'application

Indications d'application: Flow cytometry: Recommended dilution: 1-4 μg/mL. Intracellular staining.

Commentaires:

The purified antibody is conjugated with Biotin-LC-NHS under optimum conditions. The reagent is free of unconjugated biotin.

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Do not freeze.
Avoid prolonged exposure to light.

Stock: 4 °C

Stockage commentaire: Store at 2-8°C. Do not freeze.

Références pour anticorps anti-HLAG (Biotin) (ABIN94381)

Poláková, Železníková, Russ: "HLA-G5 in the blood of leukemia patients and healthy individuals." dans: Leukemia research, Vol. 37, Issue 2, pp. 139-45, (2013) (PubMed).

Lafon, Prehaud, Megret, Lafage, Mouillot, Roa, Moreau, Rouas-Freiss, Carosella: "Modulation of HLA-G expression in human neural cells after neurotropic viral infections." dans: Journal of virology, Vol. 79, Issue 24, pp. 15226-37, (2005) (PubMed).

Le Rond, Gonzalez, Gonzalez, Carosella, Rouas-Freiss: "Indoleamine 2,3 dioxygenase and human leucocyte antigen-G inhibit the T-cell alloproliferative response through two independent pathways." dans: Immunology, Vol. 116, Issue 3, pp. 297-307, (2005) (PubMed).

Rebmann, Lemaoult, Rouas-Freiss, Carosella, Grosse-Wilde: "Report of the Wet Workshop for Quantification of Soluble HLA-G in Essen, 2004." dans: Human immunology, Vol. 66, Issue 8, pp. 853-63, (2005) (PubMed).

Le Rond, Le Maoult, Créput, Menier, Deschamps, Le Friec, Amiot, Durrbach, Dausset, Carosella, Rouas-Freiss: "Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients." dans: European journal of immunology, Vol. 34, Issue 3, pp. 649-60, (2004) (PubMed).

Détails sur HLAG

Antigène: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Autre désignation: HLA-G (HLAG Produits)

Synonymes: anticorps MHC-G, anticorps B-F, anticorps B-F-S04, anticorps B-F-S05, anticorps B-F-S06, anticorps B-F-S07, anticorps B-FI, anticorps B-FIV, anticorps BF2, anticorps BFa2, anticorps BFw-03, anticorps BFw-05, anticorps BFz-01, anticorps major histocompatibility complex, class I, G, anticorps MHC BF1 class I, anticorps HLA-G, anticorps BF1

Sujet: Major histocompatibility complex, class I, G,Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.

ID gène: 3135

UniProt: P17693

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints